Given that PI3K pathway hyperactivation is linked to tumor proliferation and resistance to targeted therapy, it is plausible that these genomic alterations contribute to the aggressive clinical trajectory observed in early‐onset CRC among Hispanic/Latino patients. The gene discussed is PIK3CG; the disease is neoplasm.